The US Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in ...
FDA Approves Supernus Pharmaceuticals’ Onapgo for Managing Motor Fluctuations in Parkinson Disease
Approval of Onapgo (apomorphine hydrochloride) marks the first and only subcutaneous apomorphine infusion device for managing ...
The agency approved Onapgo, a new Parkinson’s disease treatment from Supernus Pharmaceuticals. Cour Pharmaceuticals secured FDA Clearance of IND Application for CNP-103 in Type 1 Diabetes. The FDA ...
The U.S. Food and Drug Administration (FDA) has approved Onapgo (apomorphine hydrochloride) injection, the first and only ...
The US Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in ...
In this Pharmaceutical Executive video interview, Ian Baer, Founder & CEO of Sooth, identifies how uncertainty of where to find information, coupled with distrust, can damage the relationship between ...
Susvimo was nonferior to intravitreal ranibizumab based on the change from baseline in distance best corrected visual acuity score. The Food and Drug Administration (FDA) has approved Susvimo ...
Findings showed tocilizumab-anoh had comparable efficacy, pharmacokinetics, safety, and immunogenicity with Actemra. The Food and Drug Administration (FDA) has approved Avtozma ® (tocilizumab ...
Objectives: This study aimed to identify, measure and evaluate expected costs of innovative palonosetron-based antiemetic therapy versus ondansetron-based treatment, the ultimate aim being to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback